gatifloxacin has been researched along with Bacterial Eye Infections in 67 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 7.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "To study the use of prophylactic fourth-generation fluoroquinolone antibiotics, gatifloxacin and moxifloxacin, and bacterial sensitivity in cases of acute postoperative endophthalmitis following cataract surgery." | 7.73 | Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. ( Deramo, VA; Fastenberg, DM; Lai, JC; Udell, IJ, 2006) |
| "To compare pharmacodynamic indices and minimal inhibitory concentrations for vancomycin, gatifloxacin, moxifloxacin, linezolid, and combined quinupristin and dalfopristin for historic and current human coagulase-negative staphylococcus (CoNS) endophthalmitis isolates." | 3.74 | In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates. ( Flynn, HW; Harper, T; Miller, D, 2007) |
| "Topical therapy with gatifloxacin before and after intraocular bacteria challenge led to lower incidences of endophthalmitis in rabbits." | 3.74 | Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis. ( Haugen, B; Haymore, J; Kleinmann, G; Mamalis, N; Olson, RJ; Romaniv, N; Werner, L, 2008) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 3.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "To study the use of prophylactic fourth-generation fluoroquinolone antibiotics, gatifloxacin and moxifloxacin, and bacterial sensitivity in cases of acute postoperative endophthalmitis following cataract surgery." | 3.73 | Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. ( Deramo, VA; Fastenberg, DM; Lai, JC; Udell, IJ, 2006) |
| "The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin." | 3.72 | Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003) |
| "To evaluate the ocular surface and aqueous antimicrobial effects of gatifloxacin and moxifloxacin administered in two dosing regimens to patients undergoing phacoemulsification." | 2.73 | Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery. ( Amico, LM; Bucci, FA; Evans, RE, 2008) |
| "Cefazolin resistance was seen in 13." | 1.72 | Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers. ( Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T, 2022) |
| " Two modified melittin peptides displayed rapid bactericidal properties against antibiotic-resistant strains, low innate resistance development by pathogenic bacteria, remained nonimmunogenic for T lymphocytes, and increased bioavailability in tear fluids." | 1.56 | Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. ( Agrawal, R; Barathi, VA; Beuerman, RW; Chan, LW; Jie, TY; Koh, SK; Lakshminarayanan, R; Leng, ET; Mayandi, V; Sebastian, TM; Somaraju Chalasani, ML; Ting, DSJ; Urf Turabe Fazil, MH; Varadarajan, J; Verma, NK; Xi, Q; Zhou, L, 2020) |
| "The developed system is a viable alternative to conventional eyedrops of GTN due to its ability to enhance bioavailability through its longer precorneal residence time." | 1.43 | Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel. ( Kant, S; Kesavan, K; Pandit, JK, 2016) |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| "Besifloxacin-treated eyes had significantly lower CFU recovered as compared with that of gatifloxacin- and moxifloxacin-treated eyes (P < 0." | 1.37 | Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. ( Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A, 2011) |
| "Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin, and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea." | 1.36 | Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. ( Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A, 2010) |
| "Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection." | 1.35 | Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. ( Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A, 2009) |
| "Bacterial endophthalmitis is a potential complication of ICL implantation." | 1.35 | Culture-positive endophthalmitis after implantation of intraocular Collamer lens. ( Cohen, JA; Davis, MJ; Dennis, RF; Epstein, RJ, 2009) |
| "Ciprofloxacin was the most statistically potent fluoroquinolone for Pseudomonas spp." | 1.34 | In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil. ( D'Azevedo, PA; Francisco, W; Oliveira, AD, 2007) |
| "Use the ID(50) (infectious dose to 50% of experimental animals) to quantify the most effective prophylactic dosing regimen to use with gatifloxacin 0." | 1.34 | Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model. ( Friday, JW; Kleinert, LB; Nix, DE; Patula, VB; Slade, DS; Snyder, RW, 2007) |
| "To compare the effects of the commercial formulations of moxifloxacin and gatifloxacin on rabbit corneal epithelium using two dosing protocols: high-frequency dosing for bacterial keratitis and cataract surgery prophylaxis." | 1.33 | Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols. ( Herrygers, LA; Lane, LC; Levine, JM; Noecker, RJ, 2005) |
| "Gatifloxacin was the most potent antimicrobial agent tested for isolates from each European country as measured by pure MIC or percentage resistance (using 95% confidence intervals)." | 1.32 | Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. ( Burnett, R; Morrissey, I; Robbins, M; Viljoen, L, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 46 (68.66) | 29.6817 |
| 2010's | 19 (28.36) | 24.3611 |
| 2020's | 2 (2.99) | 2.80 |
| Authors | Studies |
|---|---|
| Mayandi, V | 1 |
| Xi, Q | 1 |
| Leng, ET | 1 |
| Koh, SK | 1 |
| Jie, TY | 1 |
| Barathi, VA | 1 |
| Urf Turabe Fazil, MH | 1 |
| Somaraju Chalasani, ML | 1 |
| Varadarajan, J | 1 |
| Ting, DSJ | 1 |
| Beuerman, RW | 1 |
| Chan, LW | 1 |
| Agrawal, R | 1 |
| Sebastian, TM | 1 |
| Zhou, L | 1 |
| Verma, NK | 1 |
| Lakshminarayanan, R | 1 |
| Soni, T | 1 |
| Gunasekaran, R | 1 |
| Das, S | 1 |
| Mitra, S | 1 |
| Prajna, NV | 1 |
| Prajna, L | 1 |
| Sharma, S | 2 |
| Mohamed, A | 1 |
| Abdel-Meguid, AAE | 1 |
| Gabr, AF | 1 |
| Said, MM | 1 |
| Nassef, MAEH | 1 |
| Elmenofy, TMI | 1 |
| Coburn, PS | 1 |
| Miller, FC | 1 |
| LaGrow, AL | 1 |
| Land, C | 1 |
| Mursalin, H | 1 |
| Livingston, E | 1 |
| Amayem, O | 1 |
| Chen, Y | 1 |
| Gao, W | 1 |
| Zhang, L | 1 |
| Callegan, MC | 4 |
| Pettey, JH | 2 |
| Mifflin, MD | 2 |
| Kamae, K | 1 |
| McEntire, MW | 1 |
| Pettey, DH | 1 |
| Brown, H | 1 |
| Olson, RJ | 3 |
| Suzuki, T | 1 |
| Ohashi, Y | 1 |
| Kletke, SN | 1 |
| Brissette, AR | 1 |
| Gale, J | 1 |
| Kesavan, K | 1 |
| Kant, S | 1 |
| Pandit, JK | 1 |
| Romanowski, EG | 4 |
| Mah, FS | 3 |
| Kowalski, RP | 4 |
| Yates, KA | 3 |
| Gordon, YJ | 3 |
| Jensen, MK | 2 |
| Fiscella, RG | 2 |
| Moshirfar, M | 5 |
| Mooney, B | 1 |
| O'Callaghan, R | 1 |
| Ohnsman, C | 1 |
| Song, J | 1 |
| Tsuchiya, Y | 1 |
| Kobayakawa, S | 2 |
| Tsuji, A | 2 |
| Tochikubo, T | 2 |
| Lindstrom, RL | 1 |
| Holland, EJ | 1 |
| Lane, SS | 1 |
| McCulley, JP | 1 |
| Reddy, AK | 1 |
| Garg, P | 1 |
| Alam, MR | 1 |
| Gopinathan, U | 1 |
| Krishnaiah, S | 1 |
| Novosad, BD | 2 |
| Ramadan, RT | 1 |
| Wiskur, B | 1 |
| Moyer, AL | 1 |
| Betanzos-Cabrera, G | 1 |
| Juárez-Verdayes, MA | 1 |
| González-González, G | 1 |
| Cancino-Díaz, ME | 1 |
| Cancino-Díaz, JC | 1 |
| Moss, JM | 1 |
| Sanislo, SR | 1 |
| Ta, CN | 1 |
| Ooki, K | 1 |
| Sanders, ME | 3 |
| Norcross, EW | 3 |
| Moore, QC | 3 |
| Shafiee, A | 3 |
| Marquart, ME | 3 |
| Davis, MJ | 1 |
| Epstein, RJ | 1 |
| Dennis, RF | 1 |
| Cohen, JA | 1 |
| Perez-Balbuena, AL | 1 |
| Vanzzini-Zago, V | 1 |
| Garza, M | 1 |
| Cancino, DC | 1 |
| Awotesu, S | 1 |
| Eke, T | 1 |
| Shah, VM | 1 |
| Tandon, R | 1 |
| Satpathy, G | 1 |
| Nayak, N | 1 |
| Chawla, B | 1 |
| Agarwal, T | 1 |
| Sharma, N | 1 |
| Titiyal, JS | 1 |
| Vajpayee, RB | 1 |
| Sanfilippo, CM | 1 |
| Hesje, CK | 1 |
| Blair, J | 1 |
| Hodge, W | 1 |
| Al-Ghamdi, S | 1 |
| Balabanian, R | 1 |
| Lowcock, B | 1 |
| Pan, YI | 1 |
| Sherif, H | 1 |
| AlMahmoud, T | 1 |
| Fergusson, D | 1 |
| Slomovic, A | 1 |
| Fintelmann, RE | 1 |
| Hoskins, EN | 1 |
| Lietman, TM | 1 |
| Keenan, JD | 1 |
| Gaynor, BD | 1 |
| Cevallos, V | 1 |
| Acharya, NR | 1 |
| Boĭko, ÉV | 1 |
| Fokina, DV | 1 |
| Reĭtuzov, VA | 1 |
| Alekperov, SI | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Sun, ST | 1 |
| Wang, LY | 1 |
| Zhang, YQ | 1 |
| Chen, ZJ | 1 |
| Han, L | 1 |
| Yue, J | 1 |
| Mittal, V | 1 |
| Fernandes, M | 1 |
| Tungsiripat, T | 1 |
| Sarayba, MA | 2 |
| Kaufman, MB | 1 |
| Sweet, PM | 2 |
| Taban, M | 2 |
| Carpenter, TR | 1 |
| McDonnell, PJ | 2 |
| Hwang, DG | 1 |
| Morrissey, I | 1 |
| Burnett, R | 1 |
| Viljoen, L | 1 |
| Robbins, M | 1 |
| Hyon, JY | 1 |
| Joo, MJ | 1 |
| Hose, S | 1 |
| Sinha, D | 1 |
| Dick, JD | 1 |
| O'Brien, TP | 1 |
| Herrygers, LA | 1 |
| Noecker, RJ | 1 |
| Lane, LC | 1 |
| Levine, JM | 1 |
| Jensen, H | 1 |
| Zerouala, C | 1 |
| Carrier, M | 1 |
| Short, B | 1 |
| Miller, J | 1 |
| Matsuzaki, K | 1 |
| Koyama, H | 1 |
| Watabe, E | 1 |
| Hasegawa, M | 1 |
| Sato, Y | 1 |
| Kobayashi, I | 1 |
| Shamie, N | 1 |
| Reiser, BJ | 1 |
| Graff, JM | 1 |
| Kesler-Diaz, A | 1 |
| Osann, KE | 1 |
| Marx, DP | 1 |
| Kumar, R | 1 |
| Donnenfeld, RS | 1 |
| Perry, HD | 1 |
| Solomon, R | 1 |
| Jensen, HG | 1 |
| Stein, J | 1 |
| Snyder, RW | 2 |
| Wittpenn, JR | 1 |
| Donnenfeld, ED | 1 |
| Parmar, P | 1 |
| Salman, A | 1 |
| Kalavathy, CM | 1 |
| Kaliamurthy, J | 1 |
| Prasanth, DA | 1 |
| Thomas, PA | 1 |
| Jesudasan, CA | 1 |
| Mirzaian, G | 1 |
| Feiz, V | 2 |
| Kang, PC | 1 |
| Hamam, RN | 1 |
| Noureddin, B | 1 |
| Salti, HI | 1 |
| Haddad, R | 1 |
| Khoury, JM | 1 |
| Epstein, SP | 1 |
| Bottone, EJ | 1 |
| Asbell, PA | 1 |
| Deramo, VA | 1 |
| Lai, JC | 1 |
| Fastenberg, DM | 1 |
| Udell, IJ | 1 |
| Olson, R | 1 |
| Sahu, SK | 1 |
| Murthy, SI | 1 |
| Sangwan, VS | 1 |
| Thomas, R | 1 |
| Vitale, AT | 1 |
| Wegelin, JA | 1 |
| Basavanthappa, S | 1 |
| Wolsey, DH | 1 |
| Oliveira, AD | 1 |
| D'Azevedo, PA | 1 |
| Francisco, W | 1 |
| Harper, T | 1 |
| Miller, D | 1 |
| Flynn, HW | 1 |
| Slade, DS | 1 |
| Friday, JW | 1 |
| Nix, DE | 1 |
| Kleinert, LB | 1 |
| Patula, VB | 1 |
| de la Cruz, J | 1 |
| Behlau, I | 1 |
| Pineda, R | 1 |
| Mamalis, N | 2 |
| Meyer, JJ | 1 |
| Espandar, L | 1 |
| Bucci, FA | 1 |
| Amico, LM | 1 |
| Evans, RE | 1 |
| Balzli, CL | 1 |
| McCormick, CC | 1 |
| Caballero, AR | 1 |
| Huang, B | 1 |
| Wigington, L | 1 |
| Smith, E | 1 |
| Tang, A | 1 |
| O'Callaghan, RJ | 1 |
| Bohigian, GM | 1 |
| Wiskur, BJ | 1 |
| Robinson, ML | 1 |
| Farrand, AJ | 1 |
| Haugen, B | 1 |
| Werner, L | 1 |
| Romaniv, N | 1 |
| Haymore, J | 1 |
| Kleinmann, G | 1 |
| Mather, R | 1 |
| Karenchak, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Contribution of Fast Molecular Bacterial Identification by Real-time PCR in Managing of Postoperative Acute Endophthalmitis[NCT02850653] | 150 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | |||
| A Randomized Clinical Trial Comparing the Effect of Moxifloxacin Versus Gatifloxacin Following Pterygium Excision on Corneal Epithelial Healing and Epithelial Toxicity.[NCT00892918] | 40 participants (Anticipated) | Interventional | 2009-06-30 | Not yet recruiting | |||
| The Effects on Betadine 5% Penetration When Using Lidocaine 2% Jelly Versus Topical Tetracaine 0.5% for Topical Phacoemulsification Cataract Surgery.[NCT00827073] | 40 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Intracameral Levofloxacin (0.5%) Versus Intracameral Cefuroxime (1mg/0.1ml) Effect on Corneal Endothelial Cell Count and Morphology in Uneventful Phacoemulsification[NCT04212078] | Phase 1/Phase 2 | 138 participants (Anticipated) | Interventional | 2019-07-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Within 3 hours from time of culture acquisition, the samples will be vortexed for 30 seconds and 100µl aliquots will be plated onto 5% sheep blood and chocolate agar plates. These plates will be incubated with 5% carbon dioxide at 35˚ C for 72 hours. After 72 hours all plates will be read for colony count and identification of all isolates will be performed using routine microbiological methods. The natural log of bacterial bacterial colony count will be used for the outcome measure. (NCT00827073)
Timeframe: (1) Pre-antibiotics swab, and (2) Post-study medication (pre surgery)
| Intervention | Ln(bacterial colony count) (Mean) |
|---|---|
| Tetracaine 0.5% Drop | -0.14 |
| Lidocaine 2% Jelly | -0.52 |
(NCT00827073)
Timeframe: (1) Pre-antibiotics swab and (2) Post-study medication (pre surgery)
| Intervention | bacterial spceies (Mean) | |
|---|---|---|
| pre number of bacterial spices | post surgery number of bacterial speices | |
| Lidocaine 2% Jelly | 1 | 1 |
| Tetracaine 0.5% Drop | 1 | 1 |
2 reviews available for gatifloxacin and Bacterial Eye Infections
| Article | Year |
|---|---|
Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacteria | 2004 |
Zymar as an ocular therapeutic agent.
Topics: Animals; Anti-Infective Agents; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; T | 2006 |
7 trials available for gatifloxacin and Bacterial Eye Infections
| Article | Year |
|---|---|
Comparative Study Between Topical Gatifloxacin 0.5% and Moxifloxacin 0.5% as a Prophylactic Measure Before Intraocular Surgery.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Corynebacterium diphtheriae; Eye Infect | 2019 |
A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Colony Cou | 2009 |
Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefazolin; Child; Corneal U | 2010 |
Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Corneal Ulcer; Dexamethasone; Double-Blind Method; Drug Ther | 2011 |
The effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Child; Epithelium, | 2005 |
Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Bacteria; Child; Ciprofloxacin; | 2006 |
Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Antitubercular Agents; Aqueous Humor; Aza Compounds; | 2008 |
58 other studies available for gatifloxacin and Bacterial Eye Infections
| Article | Year |
|---|---|
Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Anti-Bacterial Agents; Antifungal Agents; Bac | 2020 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacte | 2022 |
Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections.
Topics: Animals; Bacterial Toxins; Biomimetic Materials; Erythrocytes; Eye Infections, Bacterial; Gatifloxac | 2019 |
The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Conjunctiva; Equipment Contamination; Eye Infections | 2013 |
Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefmenoxime; Corneal Ulcer; Drug Combinations; Drug | 2013 |
Endogenous bacterial endophthalmitis caused by Pantoea species: a case report.
Topics: Administration, Topical; Anti-Bacterial Agents; Bacteremia; Drug Therapy, Combination; Endophthalmit | 2014 |
Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel.
Topics: Alginates; Animals; Anti-Bacterial Agents; Biological Availability; Carboxymethylcellulose Sodium; C | 2016 |
Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial Flora.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antibiotic Prophyla | 2015 |
Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis.
Topics: Animals; Anti-Bacterial Agents; Benzalkonium Compounds; Corneal Stroma; Disease Models, Animal; Drug | 2008 |
Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprof | 2008 |
Laboratory data and statistical evidence in fluoroquinolone study.
Topics: Administration, Topical; Animals; Anterior Chamber; Anti-Infective Agents; Collagen; Colony Count, M | 2008 |
Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Cataract E | 2008 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye In | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye In | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinol | 2010 |
Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Evaluati | 2009 |
Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis.
Topics: Anti-Infective Agents; Aza Compounds; Conjunctivitis; Corneal Ulcer; DNA Gyrase; DNA Topoisomerase I | 2009 |
Aqueous humor penetration of fourth-generation fluoroquinolone ophthalmic solutions given by multiple administration in a rabbit model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Cataract Extraction; Drug Administrati | 2009 |
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2009 |
Culture-positive endophthalmitis after implantation of intraocular Collamer lens.
Topics: Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; | 2009 |
Atypical mycobacterium keratitis associated with penetrating keratoplasty: case report of successful therapy with topical gatifloxacin 0.3%.
Topics: Administration, Topical; Anti-Infective Agents; Corneal Ulcer; Eye Infections, Bacterial; Fluoroquin | 2010 |
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2010 |
Preoperative lidocaine gel.
Topics: Administration, Topical; Anesthetics, Local; Anti-Infective Agents; Bacteria; Colony Count, Microbia | 2010 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2011 |
Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Disk Diffusion A | 2011 |
[The effectiveness of intraocular delivery of 5-fluoroquinolones for prophylaxis of intraocular infection].
Topics: Anti-Bacterial Agents; Aza Compounds; Eye Infections, Bacterial; Eye Injuries; Female; Fluoroquinolo | 2011 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
[The changes of ocular bacterial isolates and in vitro antimicrobial susceptibility in the past six years].
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Eye; Eye Infections, Bacterial; Fluoroquinolones; | 2012 |
Cotrimoxazole-resistant Nocardia sclerokeratitis: effective therapy with fourth-generation fluoroquinolones.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Resi | 2012 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mode | 2003 |
Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002.
Topics: Administration, Topical; Anti-Bacterial Agents; Drug Resistance, Bacterial; Europe; Eye Infections, | 2004 |
Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis.
Topics: Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Co | 2004 |
Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols.
Topics: Animals; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; E | 2005 |
Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disea | 2005 |
Acinetobacter as a causative agent in preseptal cellulitis.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Anti-Infective Agents; Cellulitis; Ciprofloxacin; Dr | 2005 |
[Antimicrobial susceptibility surveillance of recent isolates from ophthalmological infections to gatifloxacin and other antimicrobial drugs].
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gati | 2005 |
The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cefazolin; Corneal Ulcer; Disease Mode | 2005 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantat | 2005 |
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cornea; Disease Models, Animal; Eye Infections, Bacte | 2006 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Topics: Adult; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Com | 2006 |
Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolone.
Topics: Adult; Amikacin; Amputation, Surgical; Anti-Bacterial Agents; Clarithromycin; Corneal Stroma; Debrid | 2006 |
Selecting between gatifloxacin and moxifloxacin drops in ambulatory ophthalmic surgery.
Topics: Ambulatory Surgical Procedures; Anti-Bacterial Agents; Aza Compounds; Drug Costs; Eye Infections, Ba | 2006 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacteria | 2006 |
Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds | 2006 |
Effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
Topics: Anti-Bacterial Agents; Aza Compounds; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolon | 2006 |
Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacter | 2007 |
In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Brazil; Ciprofloxacin; Eye Infections, Bacterial; Fl | 2007 |
In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Topics: Acetamides; Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Aqueous Humor; Aza | 2007 |
Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Colony Count, Microbial; Corneal Ulcer; Dise | 2007 |
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Disease Model | 2007 |
Atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth-generation fluoroquinolone therapy.
Topics: Adult; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacterial; Eye Infections, Bacterial; | 2007 |
The increasing problem of antibiotic resistance.
Topics: Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Drug Resistance, Bacterial; Eye Infections, Bac | 2007 |
Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis.
Topics: Adult; Amikacin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Corneal Ulcer; Doxycycline; D | 2007 |
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Corneal Stroma; Corneal Ulce | 2008 |
Endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Endophthalmitis; Eye Infecti | 2008 |
Toward improving therapeutic regimens for Bacillus endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Bacillus cereus; Biological Availability; Dexamethasone; Disease Mod | 2008 |
Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis.
Topics: Administration, Topical; Animals; Anterior Chamber; Anti-Infective Agents; Collagen; Colony Count, M | 2008 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophtha | 2002 |